Unknown

Dataset Information

0

MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer.


ABSTRACT: Tamoxifen is commonly used for the treatment of patients with estrogen receptor-positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics. Recently, long noncoding RNA MIR497HG and its embedded miR-497 and miR-195 are proved to play significant roles in many types of human cancers, but their roles in tamoxifen-resistant breast cancer remain unknown. The results indicate that MIR497HG deficiency induces breast cancer progression and tamoxifen resistance by inducing downregulation of miR-497/195. miR-497/195 coordinately represses five positive PI3K-AKT regulators (MAP2K1, AKT3, BCL2, RAF1, and CCND1), resulting in inhibition of PI3K-AKT signaling, and PI3K-AKT inhibition in tamoxifen-resistant cells restored tamoxifen responsiveness. Furthermore, ER α binds the MIR497HG promoter to activate its transcription in an estrogen-dependent manner. ZEB1 interacts with HDAC1/2 and DNMT3B at the MIR497HG promoter, resulting in promoter hypermethylation and histone deacetylation. The findings reveal that ZEB1-induced MIR497HG depletion contributes to breast cancer progression and tamoxifen resistance through PI3K-AKT signaling. MIR497HG can be used as a biomarker for predicting tamoxifen sensitivity in patients with ER+ breast cancer.

SUBMITTER: Tian Y 

PROVIDER: S-EPMC10131819 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

MIR497HG-Derived miR-195 and miR-497 Mediate Tamoxifen Resistance via PI3K/AKT Signaling in Breast Cancer.

Tian Yao Y   Chen Zhao-Hui ZH   Wu Peng P   Zhang Di D   Ma Yue Y   Liu Xiao-Feng XF   Wang Xin X   Ding Dan D   Cao Xu-Chen XC   Yu Yue Y  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20230223 12


Tamoxifen is commonly used for the treatment of patients with estrogen receptor-positive (ER+) breast cancer, but the acquired resistance to tamoxifen presents a critical challenge of breast cancer therapeutics. Recently, long noncoding RNA MIR497HG and its embedded miR-497 and miR-195 are proved to play significant roles in many types of human cancers, but their roles in tamoxifen-resistant breast cancer remain unknown. The results indicate that MIR497HG deficiency induces breast cancer progres  ...[more]

Similar Datasets

| S-EPMC8210559 | biostudies-literature
| S-EPMC8315014 | biostudies-literature
| S-EPMC8465682 | biostudies-literature
| S-EPMC11297691 | biostudies-literature
| S-EPMC6942430 | biostudies-literature
| S-EPMC3609788 | biostudies-literature
| S-EPMC5332870 | biostudies-literature
| S-EPMC4677300 | biostudies-literature
| S-EPMC6887584 | biostudies-literature
| S-EPMC8283840 | biostudies-literature